Abstract. Endometrial carcinomas producing  α-fetoprotein (AFP) are extremely rare. We report a case of AFP-producing, Grade 2 endometrioid adenocarcinoma without an obvious hepatoid component. A 59-year-old multiparous woman presented with abdominal swelling. The serum level of AFP was 1292.8 ng/ml. Magnetic resonance images of the pelvis showed a markedly enlarged uterus, with a tumor growing exophytically within the endometrial cavity. Total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed. The histopathological examination demonstrated a Stage IIA, Grade 2 endometrioid adenocarcinoma without an obvious hepatoid component. The endometrioid adenocarcinoma cells were partly positive for AFP immunoreactivity. The patient received adjuvant chemotherapy and was disease-free 60 months after the operation. This case confirms the existence of AFP-producing endometrioid adenocarcinomas without hepatoid features.

Introduction

α-fetoprotein (AFP) is a significant serum protein synthesized during fetal life, and the expression of the AFP gene is dramatically reduced after birth. Numerous cases of AFP-producing carcinomas have been reported, with stomach as the most common site (1). It has been demonstrated that AFP-producing gastric cancers are clinically aggressive and have a poor prognosis (2). However, AFP-producing endometrial tumors, with the exception of yolk sac tumors, are extremely rare, and only 12 cases of the former have been described in the English literature (3-14). In such cases, the serum level of AFP is generally elevated and AFP production can be demonstrated by immunohistochemical analysis of the cytoplasm, especially in hepatoid adenocarcinoma (HC) cells. We report on a case of AFP-producing, Grade 2 endometrioid adenocarcinoma without an obvious hepatoid component.

Case report

The patient was a 59-year-old (gravida 2, para 2) Japanese woman. Except for diabetes mellitus since the age of 57, her family and past medical history were routine. Age of menopause was 50 years. The patient presented at a local clinic complaining of abdominal swelling that had persisted for a few months. Serum AFP levels were elevated and a pelvic tumor was detected. No vaginal bleeding nor palpable lymphadenopathy were detected. A pelvic examination showed a tumor approximately the same size as a 16-week gestational uterus. No abnormalities were observed in the indices of the complete blood count and serological tests. Serum levels of AFP and CA-125 were 1292.8 ng/ml (normal <10 ng/ml) and 82.0 U/ml (normal <35 U/ml), respectively, while those of other tumor markers including CA 19-9, CA 72-4 and CEA were within the normal range. Magnetic resonance imaging of the pelvis showed a markedly enlarged uterus, with a tumor growing exophytically within the endometrial cavity along with fluid collection and an adnexal tumor. The uterine tumor was heterogeneously hypointense with scattered areas of slightly high signal intensity on T2-weighted imaging (Fig. 1A) and appeared hypointense to the myometrium on contrast-enhanced T1-weighted imaging (Fig. 1B). Computerized tomography showed no signs of lymph node, peritoneal, lung or liver metastases.

Abdominal exploration revealed a markedly enlarged uterus, and a left ovarian cyst and hydrosalpinx adhesive to the posterior wall of the uterine corpus. A small amount of ascites was present and the cytological examination was negative for malignant cells. No dissemination was observed in the peritoneal cavity. Total abdominal hysterectomy, bilateral salpingo-oophorectomy and partial omentectomy were carried out. Lymphadenectomy was not performed, since the adhesions in the pelvic cavity were extremely strong. The uterus along with the left adnexal tumor weighed 1,850 g. A histopathological examination showed a Grade 2 endometrioid adenocarcinoma invading more than half of the thickness of the myometrium, extending into the cervical mucosa, with...
lymphatic invasion and no evidence of malignancy in the left adnexal tumor (Fig. 2A). Hepatoid adenocarcinoma cells were not detected in any of the tissue sections obtained. The endometrioid adenocarcinoma cells were partially immunoreactive for AFP (Fig. 2B). The disease was consistent with Stage IIA endometrial cancer, according to the International Federation of Gynecology and Obstetrics (FIGO) classification system. The patient was intravenously administered six courses of a multidrug regimen consisting of carboplatin, theraurubicin and paclitaxel. Levels of serum AFP declined to the normal range on the 42nd postoperative day. Drug therapy was well-tolerated and the patient has remained disease-free 60 months after the operation.

Discussion

HC is a variant of adenocarcinoma that is composed of tumor cells with extensive hepatic differentiation. The first case of HC was reported in 1985 as an AFP-producing gastric carcinoma with features of hepatic differentiation (15). HC usually generates an expanding mass with scattered or extensive necrosis. Numerous cases of carcinomas with hepatoid differentiation were reported in a variety of primary organs, including the gastrointestinal tract, ovary, pancreas, lung, kidney, urinary bladder and uterus (1). HC should essentially be diagnosed on the basis of the histological features of the tumor. It is characterized by the medullary or papillotubular arrangement of tumor cells with eosinophilic and granular cytoplasm, thus resembling hepatocellular carcinoma.

In 13 reported cases of AFP-producing endometrial carcinomas, including the present case, the patients were elderly (median 63 years; range 44-68 years) (3-14). These tumors usually show an exophytic growth pattern and are histologically high-grade. Furthermore, patients are diagnosed at advanced stages and have poor prognosis. AFP expression has been demonstrated in HC cells. However, previously published reports, did not address AFP expression in HCs (4,5). In the
cases of carcinosarcoma, AFP was reported to be detected in the carcinomatous but not in the sarcomatous components (3).

The present case was unusual in comparison with most reported cases in that the tumor was not high-grade, and hepatoid features were not detected in any of its sections. Yamamoto et al reported that AFP expression was detected in endometrioid adenocarcinoma cells and was particularly strong in the hepatoid cells (7). The relationship between endometrioid adenocarcinoma and hepatoid cells is completely unknown. In our case, the aberrant differentiation of adenocarcinoma cells into cells with phenotypes of hepatocytes may be weak. Toyoda et al reported that it is difficult to determine whether an endometrial tumor produces AFP solely on the basis of the morphological features of the tumor (9). Nagai et al reported cases of HCs and AFP-positive adenocarcinomas without hepatoid features (APC) of the stomach (16). The incidence of venous invasion in HC was higher than that of APC. There were no significant differences between the two tumors regarding clinical features, macroscopic features and the incidence of lymphatic permeation. As for advanced carcinomas, the prognosis of patients with HC was poorer than that of patients with APC. Therefore, previous investigators stated that HC should be distinguished from APC. Our case suggests the occurrence of endometrial AFP-positive adenocarcinomas without hepatoid features.

Serum AFP does not commonly examined in cases of endometrial cancer. Therefore, the true frequency of endometrial AFP-producing adenocarcinomas without obvious hepatoid features remains unclear. The endometrium is a possible site of AFP-producing carcinomas and further studies are essential to clarify this issue.

References